The role of therapeutic drug monitoring in pediatric HIV/AIDS.
until further notice
SourceTherapeutic Drug Monitoring, 32, 3, (2010), pp. 269-272
1 juni 2010
Article / Letter to editor
Display more detailsDisplay less details
Therapeutic Drug Monitoring
SubjectN4i 2: Invasive mycoses and compromised host; N4i 3: Poverty-related infectious diseases; NCEBP 13: Infectious diseases and international health; NCEBP 13: Infectious diseases and international health
International guidelines do not recommend therapeutic drug monitoring (TDM) of HIV-infected children as a routine measurement as part of medical management. There are, however, several clinical scenarios in which TDM may be indicated. Underdosing may be one of the major risks, especially in younger children. No randomized controlled clinical trials have been conducted to assess the added value of TDM in HIV-infected children, making recommendations for TDM in children with HIV/AIDS merely based on expert opinion. There is a need for more descriptive studies on the usefulness of TDM in HIV-infected children to convince pediatricians worldwide to let more children benefit from TDM.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.